|
|
|
|
LEADER |
01336nmm a2200313 u 4500 |
001 |
EB002189436 |
003 |
EBX01000000000000001326921 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
231211 ||| eng |
100 |
1 |
|
|a Wang, Huihui
|
245 |
0 |
0 |
|a Ghana's Pharmacovigilance Experience
|h Elektronische Ressource
|b From Vertical Program Activity to Nationwide System
|c Huihui Wang
|
260 |
|
|
|a Washington, D.C
|b The World Bank
|c 2023
|
653 |
|
|
|a Pharmacovigilance
|
653 |
|
|
|a Health Policy and Management
|
653 |
|
|
|a Health, Nutrition and Population
|
653 |
|
|
|a Health Sector Funding
|
653 |
|
|
|a Safety Monitoring
|
653 |
|
|
|a FDA
|
700 |
1 |
|
|a Figueras Sune, Albert
|
700 |
1 |
|
|a Darko, Delese Mimi
|
700 |
1 |
|
|a Kumwenda, James
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b WOBA
|a World Bank E-Library Archive
|
490 |
0 |
|
|a 2203
|
028 |
5 |
0 |
|a 10.1596/40382
|
856 |
4 |
0 |
|u http://elibrary.worldbank.org/doi/book/10.1596/40382
|x Verlag
|3 Volltext
|
082 |
0 |
|
|a 330
|
520 |
|
|
|a The objective of this report is to examine the development of pharmacovigilance (PV) in Ghana and illustrate the role it plays in the health system, and more recently, during the COVID-19 emergency response. It concludes by offering some relevant lessons for building PV capacity in other low-and middle-income countries
|